文献速递消化道肿瘤与早癌肝病

靶向闭合蛋白-1的特异性抗体治疗肝细胞癌可抑制致癌信号并重塑肿瘤微环境

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
PubMed 文献 · J Hepatol · 2022-10-27

该临床前研究使用靶向人非连接型闭合蛋白-1(CLDN1)胞外环的人源化单克隆抗体,在肝细胞癌(HCC)细胞系模型、患者来源3D离体模型及细胞系来源与患者来源异种移植小鼠模型中验证其作用。结果显示靶向非连接型CLDN1可显著抑制肿瘤生长与侵袭,机制研究提示CLDN1调控肿瘤干性、代谢、致癌信号并扰动肿瘤免疫微环境。作者认为结果为CLDN1特异性单抗治疗晚期HCC的临床开发提供了依据。

要点

  • 靶向非连接型CLDN1的单克隆抗体在HCC细胞系及患者来源3D离体模型中显著抑制肿瘤生长与侵袭。
  • 在细胞系来源和患者来源异种移植小鼠模型中证实对肿瘤生长的显著抑制作用。
  • 单细胞RNA测序提示CLDN1调控肿瘤干性、代谢、致癌信号并扰动肿瘤免疫微环境。

核心结论

  • 靶向CLDN1为HCC治疗提供了依据,并为CLDN1特异性单抗治疗晚期HCC的临床开发铺平道路。

研究设计与样本

  • 临床前研究:使用靶向人非连接型CLDN1胞外环的人源化单克隆抗体,在患者来源细胞模型和动物模型系统中进行验证。

主要发现

  • 靶向非连接型CLDN1在HCC细胞系模型和患者来源3D离体模型中显著抑制肿瘤生长与侵袭。
  • 在大量细胞系来源异种移植和患者来源异种移植小鼠模型中证实对肿瘤生长的显著抑制作用。
  • 对多细胞患者HCC肿瘤球进行单细胞RNA测序的机制研究提示,CLDN1调控肿瘤干性、代谢、致癌信号并扰动肿瘤免疫微环境。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Despite recent approvals, the response to treatment and prognosis of patients with advanced hepatocellular carcinoma (HCC) remain poor. Claudin-1 (CLDN1) is a membrane protein that is expressed at tight junctions, but it can also be exposed non-junctionally, such as on the basolateral membrane of the human hepatocyte. While CLDN1 within tight junctions is well characterized, the role of non-junctional CLDN1 and its role as a therapeutic target in HCC remains unexplored. METHODS: Using humanized monoclonal antibodies (mAbs) specifically targeting the extracellular loop of human non-junctional CLDN1 and a large series of patient-derived cell-based and animal model systems we aimed to investigate the role of CLDN1 as a therapeutic target for HCC. RESULTS: Targeting non-junctional CLDN1 markedly suppressed tumor growth and invasion in cell line-based models of HCC and patient-derived 3D ex vivo models. Moreover, the robust effect on tumor growth was confirmed in vivo in a large series of cell line-derived xenograft and patient-derived xenograft mouse models. Mechanistic studies, including single-cell RNA sequencing of multicellular patient HCC tumorspheres, suggested that CLDN1 regulates tumor stemness, metabolism, oncogenic signaling and perturbs the tumor immune microenvironment. CONCLUSIONS: Our results provide the rationale for targeting CLDN1 in HCC and pave the way for the clinical development of CLDN1-specific mAbs for the treatment of advanced HCC. IMPACT AND IMPLICATIONS: Hepatocellular carcinoma (HCC) is associated with high mortality and unsatisfactory treatment options. Herein, we identified the cell surface protein Claudin-1 as a treatment target for advanced HCC. Monoclonal antibodies targeting Claudin-1 inhibit tumor growth in patient-derived ex vivo and in vivo models by modulating signaling, cell stemness and the tumor immune microenvironment. Given the differentiated mechanism of action, the identification of Claudin-1 as a novel therapeutic target for HCC provides an opportunity to break the plateau of limited treatment response. The results of this preclinical study pave the way for the clinical development of Claudin-1-specific antibodies for the treatment of advanced HCC. It is therefore of key impact for physicians, scientists and drug developers in the field of liver cancer and gastrointestinal oncology.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Roehlen N, Muller M, Nehme Z, et al. Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment. J Hepatol. 2022. PMID: 36309131. doi:10.1016/j.jhep.2022.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。